These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16918392)

  • 1. Molecular pathologies of and enzyme replacement therapies for lysosomal diseases.
    Sakuraba H; Sawada M; Matsuzawa F; Aikawa S; Chiba Y; Jigami Y; Itoh K
    CNS Neurol Disord Drug Targets; 2006 Aug; 5(4):401-13. PubMed ID: 16918392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Beta-N-acetyl-hexosaminidase--the enzyme of Tay-Sachs and Sandhoff diseases].
    Zwierz K; Juszkiewicz J; Arciuch L; Gindzieński A
    Postepy Biochem; 1992; 38(3):127-32. PubMed ID: 1461844
    [No Abstract]   [Full Text] [Related]  

  • 3. Genetics and Therapies for GM2 Gangliosidosis.
    Cachon-Gonzalez MB; Zaccariotto E; Cox TM
    Curr Gene Ther; 2018; 18(2):68-89. PubMed ID: 29618308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biochemical basis of gangliosidoses.
    Sandhoff K; Conzelmann E
    Neuropediatrics; 1984 Sep; 15 Suppl():85-92. PubMed ID: 6242704
    [No Abstract]   [Full Text] [Related]  

  • 5. Natural history and inherited disorders of a lysosomal enzyme, beta-hexosaminidase.
    Neufeld EF
    J Biol Chem; 1989 Jul; 264(19):10927-30. PubMed ID: 2525553
    [No Abstract]   [Full Text] [Related]  

  • 6. [Recent advances in molecular genetics of GM2 gangliosidosis].
    Wakamatsu N
    Nihon Rinsho; 1995 Dec; 53(12):2988-93. PubMed ID: 8577047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases.
    Phaneuf D; Wakamatsu N; Huang JQ; Borowski A; Peterson AC; Fortunato SR; Ritter G; Igdoura SA; Morales CR; Benoit G; Akerman BR; Leclerc D; Hanai N; Marth JD; Trasler JM; Gravel RA
    Hum Mol Genet; 1996 Jan; 5(1):1-14. PubMed ID: 8789434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoters for the human beta-hexosaminidase genes, HEXA and HEXB.
    Norflus F; Yamanaka S; Proia RL
    DNA Cell Biol; 1996 Feb; 15(2):89-97. PubMed ID: 8634145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biochemistry of HEXA and HEXB gene mutations causing GM2 gangliosidosis.
    Mahuran DJ
    Biochim Biophys Acta; 1991 Feb; 1096(2):87-94. PubMed ID: 1825792
    [No Abstract]   [Full Text] [Related]  

  • 10. A Glycoengineered Enzyme with Multiple Mannose-6-Phosphates Is Internalized into Diseased Cells to Restore Its Activity in Lysosomes.
    Hyun JY; Kim S; Lee HS; Shin I
    Cell Chem Biol; 2018 Oct; 25(10):1255-1267.e8. PubMed ID: 30146240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of recombinant beta-hexosaminidase A, a potential enzyme for replacement therapy for Tay-Sachs and Sandhoff diseases, in the methylotrophic yeast Ogataea minuta.
    Akeboshi H; Chiba Y; Kasahara Y; Takashiba M; Takaoka Y; Ohsawa M; Tajima Y; Kawashima I; Tsuji D; Itoh K; Sakuraba H; Jigami Y
    Appl Environ Microbiol; 2007 Aug; 73(15):4805-12. PubMed ID: 17557860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases.
    Huang JQ; Trasler JM; Igdoura S; Michaud J; Hanal N; Gravel RA
    Hum Mol Genet; 1997 Oct; 6(11):1879-85. PubMed ID: 9302266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of hexosaminidase A activity in human Tay-Sachs fibroblasts via adenoviral vector-mediated gene transfer.
    Akli S; Guidotti JE; Vigne E; Perricaudet M; Sandhoff K; Kahn A; Poenaru L
    Gene Ther; 1996 Sep; 3(9):769-74. PubMed ID: 8875224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structure of human beta-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease.
    Mark BL; Mahuran DJ; Cherney MM; Zhao D; Knapp S; James MN
    J Mol Biol; 2003 Apr; 327(5):1093-109. PubMed ID: 12662933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical consequences of mutations causing the GM2 gangliosidoses.
    Mahuran DJ
    Biochim Biophys Acta; 1999 Oct; 1455(2-3):105-38. PubMed ID: 10571007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuronal lysosomal enzyme replacement using fragment C of tetanus toxin.
    Dobrenis K; Joseph A; Rattazzi MC
    Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2297-301. PubMed ID: 1532255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The beta-hexosaminidase deficiency disorders: development of a clinical paradigm in the mouse.
    Tifft CJ; Proia RL
    Ann Med; 1997 Dec; 29(6):557-61. PubMed ID: 9562524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological evaluation of enantiomeric beta-N-acetylhexosaminidase inhibitors LABNAc and DABNAc as potential agents against Tay-Sachs and Sandhoff disease.
    Rountree JS; Butters TD; Wormald MR; Boomkamp SD; Dwek RA; Asano N; Ikeda K; Evinson EL; Nash RJ; Fleet GW
    ChemMedChem; 2009 Mar; 4(3):378-92. PubMed ID: 19145603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sialidase-mediated depletion of GM2 ganglioside in Tay-Sachs neuroglia cells.
    Igdoura SA; Mertineit C; Trasler JM; Gravel RA
    Hum Mol Genet; 1999 Jun; 8(6):1111-6. PubMed ID: 10332044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism.
    Sango K; Yamanaka S; Hoffmann A; Okuda Y; Grinberg A; Westphal H; McDonald MP; Crawley JN; Sandhoff K; Suzuki K; Proia RL
    Nat Genet; 1995 Oct; 11(2):170-6. PubMed ID: 7550345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.